The renin–angiotensin–aldosterone system (RAAS) is a major hormone pathway that regulates blood pressure and body fluid levels, and is involved in organ injuries. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), both of which block the downstream components of RAAS, are highly effective in controlling blood pressure and have organ protective effects, mainly on the heart and kidneys. Renin is a key upstream molecule of RAAS and its inhibition seems to result in more effective treatment than that of downstream components. However, the clinical application of a renin inhibitor is largely limited owing to the lack of efficacy.
Imarikiren (SCO-272, formerly TAK-272) is a long-acting renin inhibitor that shows excellent pharmacokinetic profiles in humans. Imarikiren has been shown to be effective in the treatment of hypertension, kidney diseases, and heart failure in preclinical studies. In addition, imarikiren sustains renin inhibition and decreases albuminuria in patients with type 2 diabetes.
These observations suggest that imarikiren is a novel drug candidate for the treatment of hypertension, kidney diseases, and heart failure.
Imarikiren is available as an injection, which is unusual for such a drug. Its efficacy is being investigated not only in acute treatment of hypertensive emergencies and acute heart failure, but also for blood pressure control and cardioprotection during dialysis via a vascular access.
SCOHIA is actively seeking partnerships worldwide for the development and commercialization of SCO-272 (Contact here for partnering).
- Diabetic kidney disease
ACE : Angiotensin-converting enzyme
ARB : Angiotensin receptor blocker